Premium
Use of hypoxia‐inducible factor signal transduction pathway to measure O 2 levels and modulate growth factor pathways
Author(s) -
Mogford Jon E.,
Roy Nakshatra K.,
Cross Kevin J.,
Mustoe Thomas A.
Publication year - 2003
Publication title -
wound repair and regeneration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.847
H-Index - 109
eISSN - 1524-475X
pISSN - 1067-1927
DOI - 10.1046/j.1524-475x.2003.11620.x
Subject(s) - transcription factor , microbiology and biotechnology , signal transduction , hypoxia (environmental) , biology , wound healing , effector , extracellular matrix , growth factor , ectopic expression , hypoxia inducible factors , gene , immunology , chemistry , genetics , receptor , oxygen , organic chemistry
Tissue PO 2 levels are known to directly modulate numerous processes involved in the reparative response to cutaneous tissue injury, including cell differentiation and migration, extracellular matrix synthesis and maturation, and effectiveness of endogenous and exogenous growth factors. Oxygen is therefore likely the critical variable determining the healing capabilities of any tissue. Significant advances in the understanding of cutaneous wound healing progressed with advances in the measurement of tissue PO 2 , which has advanced over the past several decades from implantable probes to now include molecular tools such as the transcription factor hypoxia inducible factor‐1 (HIF‐1). HIF‐1 modulates the expression of genes that drive the cellular adaptive response to hypoxia and possess the HIF‐1 binding sequence named hypoxia response element within their promoter sequence. Molecular biology techniques are now allowing exploitation of the HIF‐1/hypoxia response element pathway to drive the expression of potential vulnerary ectopic genes. Here we show the utility of the hypoxia response element for hypoxia‐driven expression of the transforming growth factor‐β–signaling component Smad3 in vitro and the in vivo detection of ischemic hypoxia using luciferase. Smad3 is a positive effector of transforming growth factor‐β superfamily signal transduction. Such approaches are the latest evolution of work championed by Hunt and colleagues over the past 4 decades. (WOUND REP REG 2003;11:496–503)